



Part 6

Lecture 2 Survival Analysis - Non Parametric



Who we are...

Pascal Tyrrell, PhD *Associate Professor*

Department of Medical Imaging , Faculty of Medicine
Department of Statistical Sciences , Faculty of Arts and Science

Paul Corey, PhD *Professor Emeritus*

Biostatistics Program, Dalla Lana Faculty of Public Health
Institute of Medical Science, Faculty of Medicine
Department of Statistical Sciences, Faculty of Arts and Science



STUDY 2 LIFETEST PROCEDURE

Forty rats are randomly allocated to two groups of 20 animals. In one group the rats were exposed to a carcinogen and in the other group they were exposed to a placebo.

The outcome variable was the time in days from randomization to death.



```

PROC      FORMAT ; VALUE RX 1 = "DRUG X" 0 ="PLACEBO" ; RUN ;
DATA EXPOSED ; INPUT DAYS STATUS TREATMENT SEX $ @@ ;
FORMAT TREATMENT RX. ; DATALINES ;
179 1 1 F 378 0 1 M 256 1 1 F 355 1 1 M 262 1 1 M
319 1 1 M 256 1 1 F 256 1 1 M 255 1 1 M 171 1 1 F
224 0 1 F 325 1 1 M 225 1 1 F 325 1 1 M 287 1 1 M
217 1 1 F 319 1 1 M 255 1 1 F 264 1 1 M 256 1 1 F
237 0 0 F 291 1 0 M 156 1 0 F 323 1 0 M 270 1 0 M
253 1 0 M 257 1 0 M 206 1 0 F 242 1 0 M 206 1 0 F
157 1 0 F 237 1 0 M 249 1 0 M 211 1 0 F 180 1 0 F
229 1 0 F 226 1 0 F 234 1 0 F 268 0 0 M 209 1 0 F
RUN ;

ODS GRAPHICS ON ;
TITLE1 " FIRST OF 3 ANALYSES " ;
PROC LIFETEST DATA = EXPOSED
plots=(survival(atrisk=0 to 1000 by 100 test)
loglogs
logsurv);
TIME DAYS * STATUS ( 0 ) ;
STRATA TREATMENT ; RUN ;
ODS GRAPHICS OFF ;

```



Summary of the Number of Censored and Uncensored Values

Stratum	TREATMENT	Total	Failed	Censored	Percent Censored
1	DRUG X	20	18	2	10.00
2	PLACEBO	20	18	2	10.00
Total		40	36	4	10.00

Summary Statistics for Time Variable DAYS

Quartile Estimates				
Percent	Point Estimate	95% Confidence Interval		
		Transform	[Lower	Upper]
75	319.000	LOGLOG	256.000	355.000
50	256.000	LOGLOG	255.000	319.000
25	255.000	LOGLOG	171.000	256.000

Mean	Standard Error
271.131	11.877

Note: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time

The LIFETEST Procedure

Stratum 1: TREATMENT = DRUG X

Product-Limit Survival Estimates					
DAYS	Survival	Failure	Survival Standard Error	Number Failed	Number Left
0.000	1.0000	0	0	0	20
171.000	0.9500	0.0500	0.0487	1	19
179.000	0.9000	0.1000	0.0671	2	18
217.000	0.8500	0.1500	0.0798	3	17
224.000 *	.	.	.	3	16
225.000	0.7969	0.2031	0.0908	4	15
255.000	.	.	.	5	14
255.000	0.6906	0.3094	0.1053	6	13
256.000	.	.	.	7	12
256.000	.	.	.	8	11
256.000	.	.	.	9	10
256.000	0.4781	0.5219	0.1146	10	9
262.000	0.4250	0.5750	0.1135	11	8
264.000	0.3719	0.6281	0.1111	12	7
287.000	0.3187	0.6813	0.1071	13	6
319.000	.	.	.	14	5
319.000	0.2125	0.7875	0.0942	15	4
325.000	.	.	.	16	3
325.000	0.1062	0.8938	0.0710	17	2
355.000	0.0531	0.9469	0.0517	18	1
378.000 *	.	.	.	18	0

Note: The marked survival times are censored observations.



The LIFETEST Procedure

Stratum 2: TREATMENT = PLACEBO

Summary Statistics for Time Variable DAYS

Quartile Estimates				
Percent	Point Estimate	95% Confidence Interval		
		Transform	[Lower	Upper)
75	257.000	LOGLOG	237.000	323.000
50	235.500	LOGLOG	206.000	253.000
25	207.500	LOGLOG	156.000	229.000

Mean	Standard Error
235.156	10.211

Product-Limit Survival Estimates


DAYS	Survival	Failure	Survival Standard Error	Number Failed	Number Left
0.000	1.0000	0	0	0	20
156.000	0.9500	0.0500	0.0487	1	19
157.000	0.9000	0.1000	0.0671	2	18
180.000	0.8500	0.1500	0.0798	3	17
206.000	.	.	.	4	16
206.000	0.7500	0.2500	0.0968	5	15
209.000	0.7000	0.3000	0.1025	6	14
211.000	0.6500	0.3500	0.1067	7	13
226.000	0.6000	0.4000	0.1095	8	12
229.000	0.5500	0.4500	0.1112	9	11
234.000	0.5000	0.5000	0.1118	10	10
237.000	0.4500	0.5500	0.1112	11	9
237.000 *	.	.	.	11	8
242.000	0.3938	0.6063	0.1106	12	7
249.000	0.3375	0.6625	0.1082	13	6
253.000	0.2813	0.7188	0.1038	14	5
257.000	0.2250	0.7750	0.0971	15	4
268.000 *	.	.	.	15	3
270.000	0.1500	0.8500	0.0891	16	2
291.000	0.0750	0.9250	0.0693	17	1
323.000	0	1.0000	.	18	0

Note: The marked survival times are censored observations.



Product-Limit Survival Estimates

With Number of Subjects at Risk




Test of Equality over Strata


Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	5.6485	1	0.0175
Wilcoxon	5.0312	1	0.0249
-2Log(LR)	0.1983	1	0.6561



Negative Log of Estimated Survivor Functions



Log of Negative Log of Estimated Survivor Functions



RESULTS OF THE TWO-SAMPLE TESTS

Rank tests for homogeneity result in a significant difference between treatments ($p = 0.018$ for LOG-RANK & $p = 0.025$ for WILCOXON test).

DRUG treated rats live significantly longer than those on the PLACEBO.

Because the survival curves for the two treatments differ primarily at longer survival times, and the Wilcoxon test places more weight on short survival times, it becomes less significant than the log-rank test, that is, a larger p value.

TEST	CHI-SQUARE	DF	PR>	CHI-SQUARE
LOG-RANK	5.6485	1		0.0175
WILCOXON	5.0312	1		0.0249



FIRST ANALYSIS PLACEBO

COMPARING DRUG AND

GROUP	MEDIAN	MEAN	STD ERROR	DF	CHI - SQUARE	P - VALUE
DRUG	256.0	271.13	11.877	1	5.649	0.0175 *
PLACEBO	235.5	235.16	10.211	1	5.031	0.0249 #

* LOG RANK TEST

WILCOXON TEST



Suppose male and female rats have different survival rates.

Therefore we test the treatment effect adjusted for the SEX effect. The variable SEX in the STRATA statement is a stratifying variable and the main variable TREATMENT is the GROUP= option.

The test statistics for the TREATMENT variable are computed by pooling over the strata defined by the values of SEX, thus controlling for the SEX effect. The NOTABLE option is added to avoid estimating a survival curve for each sex.



If variable SEX is associated with group variable TREATMENT then including it in the STRATA statement as a predictor will lower the residual variation and **lower** the p value for the TREATMENT variable.

```
TITLE1    " SECOND ANALYSIS INCLUDES SEX VARIABLE " ;  
PROC LIFETEST DATA = EXPOSED NOTABLE ;  
TIME DAYS * STATUS ( 0 ) ;  
STRATA SEX / GROUP = TREATMENT ; RUN ;
```

SECOND ANALYSIS

STRATIFIED TEST OF EQUALITY OVER GROUP

TEST	CHI SQUARE	DF	PR>CHI-SQUARE
LOG-RANK	7.2466	1	0.0071
WILCOXON	5.9179	1	0.0150

LESSON LEARNED

You may want to show that an EXPOSURE variable such as DRUG or DIET is related to an OUTCOME variables such as DEATH or change in BLOOD PRESSURE.

You may include in your analysis a variable such as AGE or SEX... for 2 reasons!

- ❑ If it is a predictor of the OUTCOME variable then including it in your model will reduce the background random variation thereby reducing the standard error of the OUTCOME variable and reduce the p value.
- ❑ If the predictor variable is also related to the EXPOSURE variable the size of the impact of the EXPOSURE variable may become larger or smaller. The predictor variable is then called a CONFOUNDER.



End of Lecture 2

Next up in Part 7 Lecture 1: Count Data!

